友芝友生物(02496.HK)M701恶性腹水II期研究数据在ESMO-ASIA会议公布

阿斯达克财经2024-12-10

友芝友生物－Ｂ(02496.HK) 公布，公司自主研发的上皮细胞黏附分子和分化簇3双靶向的在研双特异性抗体药物M701在中国开展的治疗晚期上皮实体瘤引发的恶性腹水的II期临床研究的更新数据已以大会口头报告的形式在2024年欧洲肿瘤内科学会亚洲分会上公布。结论是M701腹腔输注对比腹腔穿刺引流，能显著延长晚期上皮性肿瘤伴症状性恶性腹水患者的无穿刺生存时间，同时，在安全性上，M701安全性也是可以接受...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2490621043?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230913084201322_s.jpg","is_english":false,"pubTime":"2024-12-10 23:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490621043","market":"sh","top_or_hot":-1,"title":"友芝友生物(02496.HK)M701恶性腹水II期研究数据在ESMO-ASIA会议公布","media":"阿斯达克财经","content":"<div>\n<p>友芝友生物－Ｂ(02496.HK) 公布，公司自主研发的上皮细胞黏附分子和分化簇3双靶向的在研双特异性抗体药物M701在中国开展的治疗晚期上皮实体瘤引发的恶性腹水的II期临床研究的更新数据已以大会口头报告的形式在2024年欧洲肿瘤内科学会亚洲分会上公布。结论是M701腹腔输注对比腹腔穿刺引流，能显著延长晚期上皮性肿瘤伴症状性恶性腹水患者的无穿刺生存时间，同时，在安全性上，M701安全性也是可以接受...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1403133/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>友芝友生物(02496.HK)M701恶性腹水II期研究数据在ESMO-ASIA会议公布</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n友芝友生物(02496.HK)M701恶性腹水II期研究数据在ESMO-ASIA会议公布\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 23:50 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1403133/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>友芝友生物－Ｂ(02496.HK) 公布，公司自主研发的上皮细胞黏附分子和分化簇3双靶向的在研双特异性抗体药物M701在中国开展的治疗晚期上皮实体瘤引发的恶性腹水的II期临床研究的更新数据已以大会口头报告的形式在2024年欧洲肿瘤内科学会亚洲分会上公布。结论是M701腹腔输注对比腹腔穿刺引流，能显著延长晚期上皮性肿瘤伴症状性恶性腹水患者的无穿刺生存时间，同时，在安全性上，M701安全性也是可以接受...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1403133/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02496","symbol_name":"友芝友生物-B","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1403133/latest-news/AAFN","article_id":"2490621043","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230913084201322_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1403133/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2490621043","pubTimestamp":1733845800,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"友芝友生物－Ｂ(02496.HK) 公布，公司自主研发的上皮细胞黏附分子和分化簇3双靶向的在研双特异性抗体药物M701在中国开展的治疗晚期上皮实体瘤引发的恶性腹水的II期临床研究的更新数据已以大会口头报告的形式在2024年欧洲肿瘤内科学会亚洲分会上公布。结论是M701腹腔输注对比腹腔穿刺引流，能显著延长晚期上皮性肿瘤伴症状性恶性腹水患者的无穿刺生存时间，同时，在安全性上，M701安全性也是可以接受的，没有观察到重要的安全风险。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02496":"友芝友生物-B","BK1161":"生物科技"},"translate_title":"Youzhiyou Biotech (02496. HK) M701 Malignant Ascites Phase II Study Data Announced at ESMO-ASIA Conference","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02496":1},"content_text":"友芝友生物－Ｂ(02496.HK) 公布，公司自主研发的上皮细胞黏附分子和分化簇3双靶向的在研双特异性抗体药物M701在中国开展的治疗晚期上皮实体瘤引发的恶性腹水的II期临床研究的更新数据已以大会口头报告的形式在2024年欧洲肿瘤内科学会亚洲分会上公布。结论是M701腹腔输注对比腹腔穿刺引流，能显著延长晚期上皮性肿瘤伴症状性恶性腹水患者的无穿刺生存时间，同时，在安全性上，M701安全性也是可以接受的，没有观察到重要的安全风险。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490621043","isCrawlerRequest":true}